Products
Our pipeline: Delivering first-in-class immunotherapies of activation and regulation
Complementary Platforms and Balanced Pipeline
- Immuno-Oncology
- Immuno-Inflammation
Product
Mono/Combo
Indication
Preclinical
Phase 1
Phase 2
Phase 3
BI 765063 (SIRPa antagonist)
+ Ezabenlimab + Erbitux/chemo/BI 836880
HNSCC (2L) / HCC (1L/2L) - BI
Significant partnerships with Servier, Boehringer Ingelheim and Veloxis Pharmaceuticals for up to €1.6Bn in milestones (€95 M already received since 2016)
The 3 areas of expertise
Three areas of expertise are being developed within our immunology research platform:
- T-cell based vaccination
- Immuno-Oncology (focus on myeloid targets)
- Auto-Immunity & Inflammation